NCT05795335 CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer
| NCT ID | NCT05795335 |
| Status | Recruiting |
| Phase | — |
| Sponsor | RenJi Hospital |
| Condition | Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 172 participants |
| Start Date | 2023-04-30 |
| Primary Completion | 2026-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 172 participants in total. It began in 2023-04-30 with a primary completion date of 2026-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an ambispective, single-center study to evaluate the survival outcomes, adverse events and predictive biomarkers for CDK4/6 inhibitors in patients with hormone receptor-positive advanced breast cancer.
Eligibility Criteria
Inclusion Criteria: * Aged ≥18 and older * Confirmed diagnosis of hormone receptor-positive breast cancer. * Subjects with locoregionally recurrent or metastatic disease not amenable to curative therapy. * Subjects have received or plan to receive CDK4/6 inhibitors for advanced disease. * ECOG 0-2 * Adequate organ function Exclusion Criteria: * Subjects disable to swallow pills. * History of immunodeficiency disease
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05795335 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05795335 currently recruiting?
Yes, NCT05795335 is actively recruiting participants. Contact the research team at wuziping@renji.com for enrollment information.
Where is the NCT05795335 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT05795335 clinical trial?
NCT05795335 is sponsored by RenJi Hospital. The trial plans to enroll 172 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.